Incannex Healthcare Limited (IXHL) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
207/11 Solent Circuit
Sydney, NSW 2153
Australia
Phone
61 4 2570 3805
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9
First IPO Date
March 02, 2022
| Name | Title | Pay | Year Born |
| Joel Bradley Latham | President, Chief Executive Officer & Executive Director | 1.13M | 1989 |
| John Michailidis EMBA | Chief Executive Officer of IncannexTM | 0 | N/A |
| Lekhram Changoer | Chief Technology Officer & Member of Advisory Board | 137,645 | 1967 |
| Joseph Swan | Chief Financial Officer, Treasurer & Secretary | 201,193 | 1991 |
| Luigi Barbato | Chief Medical Officer | 379,194 | N/A |
| Natalie May | Head of Clinical Operations | 0 | N/A |
| Mark Bleackley | Chief Scientific Officer, Head of Programs & Member of the Advisory Board | 0 | N/A |
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.